Cardioprotective Effects of Endogenous Erythropoietin in Patients Undergoing Coronary Artery Bypass Surgery

Cliniques universitaires Saint-Luc- Université Catholique de Louvain

Status: Completed

Conditions: Cardiac Surgery

Treatments: Procedure: acute normovolemic hemodilution

Study type: Interventional

Funder types: Other

Identifiers

NCT00854217

2009/03FEV/047

Details and patient eligibility

About

Several studies have highlighted the cardioprotective effects of acute normovolemic hemodilution during cardiac surgery. The aim of our study is to show that an increase in endogenous erythropoietin (EPO) might explain the cardioprotective effects of acute normovolemic hemodilution against ischemia-reperfusion phenomena.

Full description

The major physiologic function of EPO is thought to be the induction of erythropoiesis. However, a growing body of evidence indicates that EPO has tissue-protective effects and prevents tissue damage during ischemia. In an ex vivo proof-of-concept, protective effects of EPO have been shown in human myocardium.

Several studies have demonstrated that acute normovolemic hemodilution before aortic cross clamping decreases perioperative myocardial damage. We hypothesized that the onset of acute anemia increases the endogenous EPO concentration, which explains the cardioprotective effects of acute normovolemic hemodilution.

Enrollment: 40 estimated patients

Sex: All

Ages: 18 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• patients between 18 and 80 years old undergoing CABG with or without cardiopulmonary bypass

Exclusion criteria

• emergencies
• redo operations
• combined surgery
• men with Hb< 120g/dL and women with Hb< 110g/ dL
• patients with preoperative creatinine> 2.2 mg/dL
• poor ventricular function (EF < 50%)
• subjects with a pulmonary disease, hepatic disease
• subjects with carotid stenosis

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Single Group Assignment

Masking: Single Blind

---

40 participants in 1 patient group, including a placebo group

placebo, hemodilution

Placebo Comparator group

Treatment:

Procedure: acute normovolemic hemodilution